Abstract

Mutations in the MMADHC gene cause cobalamin D disorder (cblD), an autosomal recessive inborn disease with defects in intracellular cobalamin (cbl, vitamin B12) metabolism. CblD patients present methylmalonic aciduria (MMA), homocystinuria (HC), or combined MMA/HC, and usually suffer developmental delay and cognitive deficits. The most frequent MMADHC genetic alterations associated with disease generate MMADHC truncated proteins, in many cases due to mutations that create premature termination codons (PTC). In this study, we have performed a comprehensive and global characterization of MMADHC protein variants generated by all annotated MMADHC PTC mutations in cblD patients, and analyzed the potential of inducible translational PTC readthrough to reconstitute MMADHC biosynthesis. MMADHC protein truncation caused by disease-associated PTC differentially affected the alternative usage of translation initiation sites, protein abundance, and subcellular localization of MMADHC. Aminoglycoside compounds induced translational PTC readthrough of MMADHC truncated variants, allowing the biosynthesis of full-length MMADHC in a PTC-specific manner. Our results suggest that translational PTC readthrough-based interventions could complement current therapies for cblD patients carrying specific MMADHC PTC mutations.

Highlights

  • Cobalamin or vitamin B12 is one of the most essential enzy­ matic cofactors in cells, and it is required for normal cellular meta­ bolism

  • Alternative usage of initiation Met codons during MMADHC protein translation has been found in cells from cobalamin D disorder (cblD) patients carrying specific premature termination codons (PTC) mutations at MMADHC gene [18]

  • The metabolic cblD-type disorder is a very rare disease in which the MMADHC gene is targeted by PTC mutations with relative high frequency

Read more

Summary

Introduction

Cobalamin (cbl) or vitamin B12 is one of the most essential enzy­ matic cofactors in cells, and it is required for normal cellular meta­ bolism. MS is reactivated by the methionine synthase reductase ([methionine synthase]-methylcob(III) alamin,S-adenosyl-L-homocysteine:NADP+ oxidoreductase; EC 1.16.1.8). Disruptions in these pathways cause several cbl-related metabolic multisystem disorders (cblA to cblG, cblJ, mut), which man­ ifest with elevated levels of methylmalonic acid and/or homocysteine [5]. Among these disorders the cblD-type disorder is a unique very rare disease associated with three distinct biochemical phenotypes: methyl­ malonic aciduria (MMA), homocystinuria (HC) or combined MMA/HC [6]

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.